CTOs on the Move

ALung Technologies

www.alung.com

 
ALung Technologies has developed the Hemolung Respiratory Assist System (RAS), a dialysis-like alternative or supplement to mechanical ventilation. The Hemolung RAS provides Respiratory Dialysis,a simple, less invasive form of extracorporeal CO2 removal. By removing carbon dioxide and delivering oxygen directly to the blood, the Hemolung RAS allows the patients lungs to rest and heal. Applications of the device include preventing intubation in acute exacerbation of chronic obstructive pulmonary disease (COPD) and enabling ultra-protective ventilation in acute respiratory distress syndrome (ARDS).
  • Number of Employees: 5K-10K
  • Annual Revenue: $1-10 Million
  • www.alung.com
  • 2500 Jane St Ste 1
    Pittsburgh, PA USA 15203
  • Phone: 412.697.3370

Executives

Name Title Contact Details

Funding

ALung Technologies raised $10.53M on 12/04/2015
ALung Technologies raised $36M on 04/12/2017

Similar Companies

LDS Test

LDS Test is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mangrove Bay Dentistry

Mangrove Bay Dentistry is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeStyles Condoms

LifeStyles Condoms is a Red Bank, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neural Analytics

Neural Analytics was created in 2013 when the company`s co-founders were introduced to leading-edge technology in the UCLA Department of Neurology. Leo, Robert and Dan, along with key UCLA faculty and administrators, all saw the potential to commercialize this new technology and build an important company with the potential to help millions of patients around the world.

Shockwave Medical

Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotrispy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. In peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, IVL demonstrated safety and consistent procedure success with low procedural complications. The technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatments. And because it is built on a traditional balloon catheter platform, it integrates seamlessly with clinicians` existing workflow.